


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim 1. (Original): A compound of formula I



wherein

X is O, NH, N(C<sub>1-4</sub>)alkyl, CO or CHOH,

Y is CH or N,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

R<sub>1</sub> is hydrogen or (C<sub>1-4</sub>)alkyl,

R<sub>2</sub> is optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl or heteroaryl,

R<sub>3</sub> is CH(R<sub>e</sub>)CONR<sub>a</sub>R<sub>b</sub> or (CH<sub>2</sub>)<sub>n</sub>NR<sub>c</sub>R<sub>d</sub>,

n is 0, 1 or 2,

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen or optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, (C<sub>7-9</sub>)bicycloalkyl, 1-aza-(C<sub>7-9</sub>)bicycloalkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl or heterocyclyl, or

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group,

R<sub>e</sub> is (C<sub>1-8</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, and

R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub>, independently, are hydrogen, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkyl-SO<sub>2</sub>, cyano, nitro or halogen, in free base or acid addition salt form.

Claim 2. (Original): A compound of formula I according to claim 1 wherein

X is O, NH, N(C<sub>1-4</sub>)alkyl, CO or CHOH,

Y is CH or N,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

$R_1$  is hydrogen or  $(C_{1-4})$ alkyl,  
 $R_2$  is optionally substituted  $(C_{1-8})$ alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl $(C_{1-4})$ alkyl, aryl or heteroaryl,  
 $R_3$  is  $CH(R_e)CONR_aR_b$  or  $(CH_2)_nNR_cR_d$ ,  
 $n$  is 0, 1 or 2,  
 $R_a$ ,  $R_b$ ,  $R_c$  and  $R_d$ , independently, are hydrogen or optionally substituted  $(C_{1-8})$ alkyl,  $(C_{3-7})$ cycloalkyl,  $(C_{3-7})$ cycloalkyl $(C_{1-4})$ alkyl, aryl, aryl $(C_{1-4})$ alkyl, heteroaryl or heteroaryl $(C_{1-4})$ alkyl or  
 $R_a$ ,  $R_b$ ,  $R_c$  and  $R_d$ , together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group,  
 $R_e$  is  $(C_{1-8})$ alkyl,  $(C_{1-4})$ alkoxy $(C_{1-4})$ alkyl,  $(C_{3-7})$ cycloalkyl or  $(C_{3-7})$ cycloalkyl $(C_{1-4})$ alkyl, and  
 $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$  and  $R_9$ , independently, are hydrogen,  $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkoxy,  $(C_{1-4})$ alkyl-SO<sub>2</sub>, cyano, nitro or halogen, in free base or acid addition salt form.


Claim 3. (Original): A compound of formula I according to claim 1 wherein

$X$  is O, NH or CO,  
 $Y$  is CH or N,  
 $A$  and  $B$  are each hydrogen or together form a second bond between the carbon atoms to which they are attached,  
 $R_1$  is hydrogen,  
 $R_2$  is  $(C_{1-4})$ alkyl, or phenyl, which is unsubstituted or substituted by hydroxy, amino or halogen,  
 $R_3$  is  $CH(R_e)CONR_aR_b$  or  $(CH_2)_nNR_cR_d$ ,  
 $n$  is 0 or 1,  
 $R_a$  and  $R_b$ , independently, are hydrogen,  $(C_{1-7})$ alkyl,  $(C_{1-4})$ alkoxy $(C_{1-4})$ alkyl, benzyl, phenyl,  $(C_{3-5})$ cycloalkyl $(C_{1-4})$ alkyl, pyridyl, pyridyl $(C_{1-4})$ alkyl,  $(C_{1-4})$ alkyl piperidinyl, tetrahydropyranyl,  $(C_{7-8})$ bicycloalkyl, 1-aza- $(C_{7-9})$ bicycloalkyl;  $(C_{5-6})$ cycloalkyl substituted by hydroxy; or pyrazolyl or isoxazolyl being unsubstituted or substituted by  $(C_{1-4})$ alkyl;  
 $R_c$  and  $R_d$ , independently, are hydrogen, tetrahydronaphthyl,  $(C_{1-4})$ alkoxy tetrahydronaphthyl,  $(C_{3-5})$ cycloalkyl being unsubstituted or substituted by halophenyl; chromanyl being substituted by halogen,  $(C_{1-4})$ alkyl or  $(C_{3-7})$ cycloalkyl; or  $(C_{1-4})$ alkyl being unsubstituted or mono or disubstituted by  $(C_{5-7})$ cycloalkyl, phenyl,  $(C_{1-4})$ alkoxy phenyl, di $(C_{1-4})$ alkoxy phenyl, halophenyl, phenoxy phenyl,  $(C_{1-4})$ alkyl phenyl, hydroxy  $(C_{1-4})$ alkyl phenyl,  $(C_{1-4})$ alkoxy  $(C_{1-4})$ alkoxy phenyl, naphthyl, pyridyl, thiadiazolyl, benzimidazolyl or furyl;  
 $R_e$  is  $(C_{1-8})$ alkyl, and  
 $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$  and  $R_9$ , independently, are hydrogen or halogen, in free base or acid addition salt form.

Claim 4. (Original): A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the steps of acylating a compound of formula II



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined in claim 1, with an acid of formula III



wherein X, Y, A, B, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are as defined in claim 1, or an activated form thereof, and recovering the so obtained compound of formula I in free base or acid addition salt form.

Claim 5. (Currently amended): A compound of ~~any one of claims 1 to 3~~ in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

Claim 6. (Currently amended): A compound of ~~any one of claims 1 to 3~~ in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.

Claim 7. (Currently amended): A pharmaceutical composition comprising a compound of ~~any one of claims 1 to 3~~ in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

Claims 8-9. (Canceled)

Claim 10. (Currently amended): A method for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of ~~any one of claims 1 to 3~~ in free base or pharmaceutically acceptable acid addition salt form.

Claim 11. (Currently amended): A combination comprising a therapeutically effective amount of a compound of ~~any one of claims 1 to 3~~ in free base or pharmaceutically acceptable acid addition salt form and a second drug substance, for simultaneous or sequential administration.